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In recent years, the incredible boost in stem cell research has kindled the expectations of both patients and physicians.
Mesenchymal progenitors, owing to their availability, ease of manipulation, and therapeutic potential, have become one of the
most attractive options for the treatment of a wide range of diseases, from cartilage defects to cardiac disorders. Moreover, their
immunomodulatory capacity has opened up their allogenic use, consequently broadening the possibilities for their application. In
this review, we will focus on their use in the therapy of myocardial infarction, looking at their characteristics, in vitro and in vivo
mechanisms of action, as well as clinical trials.
1.Introduction
Although traditionally regarded as a health concern related
particularly to the industrialized world, cardiovascular dis-
eases are now the ﬁrst cause of death worldwide [1], with
myocardial infarction (MI) resulting in 12.8% of deaths.
Aside from changes in ways of life associated with economic
and social development, one of the main reasons is the fact
that MI is an evolving disease. After the ischemic event,
anaerobic conditions rapidly induce massive cell death, not
only involving cardiomyocytes (CMs), but also vascular
cells. Although the organism tries to exert a compensatory
activity (reviewed in [2]) during the ﬁrst stages of the disease
and may even manage to partially restore functionality, the
resulting scar is never repopulated, relentlessly leading the
patient towards the setting of heart failure. Thus, though
not conventionally regarded as such, cardiac disease is a
degenerative aﬀection in which lack of suﬃcient contractile
and vascular cells leads to a decompensated neurohormonal
microenvironment [3], which further impairs both organ
function and cell survival.
Although the existence of stem cells has been a well-
known fact for nearly half a century [4], it is in the last 15
years that the ﬁeld has experienced a major boost. Their
capacity for diﬀerentiation has made stem cells outstanding
candidates for the treatment of degenerative diseases, substi-
tuting for cells lost during the course of the disorder.
Consequently, cardiac diseases and MI have been the object
of intense research [5]. Among the cell types studied, mesen-
chymal stem cells (MSCs) are strong candidates for success
in the MI setting. In the following pages, we will discuss their
capacities as well as pre- and clinical investigations in which
these cells have been employed.
2.Origin,Types,andCharacteristics
The studies by Friedenstein and colleagues are regarded
as one of the ﬁrst reports on MSC [4]. In these, the
clonogenicpotentialofapopulation ofbonemarrow-(BM-)
derived stromal cells, described as colony-forming unit
ﬁbroblasts, was examined. BM is indeed one of the best-
known sources of progenitor cells, MSC being among them
[6]. Although this is not entirely understood, BM-MSC
are thought to act as supporters and nurturers of other
cells within the marrow [7–9], possibly in a location close
to blood vessels [10]. However, there is a relatively small
population(0.01%–0.0001%ofnucleatedcellsinhumanBM
[11]), so MSC can be easily puriﬁed by plastic adherence
and expanded after BM extraction. Similarly, but adding2 Stem Cells International
simple mechanical and enzymatic processing, a mixed cell
population (called stromal vascular fraction, SVF) can be
isolatedfromadiposedepots,which,afterinvitrocultureand
homogenization, gives rise to the mesenchymal progenitors
from this tissue, also termed adipose-derived stem cells
(ADSCs) [12] .A d i p o s et i s s u ei sr e g a r d e da sam u c hr i c h e r
source of progenitors, harboring 100 to 500 times the
numbers seen in BM [13]. However, despite similarities
in phenotype, diﬀerentiation, or growth kinetics, there are
certain diﬀerences at a functional, genomic, and proteomic
level [9, 14], suggesting a degree of higher commitment
of BM-MSC to chondrogenic and osteogenic lineages than
ADSC [15].
Adipose tissue and BM are the most widely researched
sources of mesenchymal progenitors because they are easy to
harvest, and owing to the relative abundance of progenitors
and the lack of ethical concerns. Nevertheless, MSCs have
been ubiquitously found in a variety of locations, as umbili-
cal cord blood [16], dental pulp [17], menstrual blood [18],
or heart [19], among others (reviewed in [20]). This wide
variety of origins, methodologies, and acronyms prompted
standardization in 2005 by the International Society for
Cellular Therapy, which set the minimum requirements
for MSC deﬁnition (Table 1). First, MSC must be plastic-
adherent when maintained in standard culture conditions.
Second, MSC must express CD105, CD73, and CD90, and
lack expression of CD45, CD34, CD14 or CD11b, CD79a,
or CD19 and HLA-DR surface molecules. Third, MSC must
diﬀerentiate to osteoblasts, adipocytes, and chondroblasts in
vitro [21]. Still, caution must be taken as some reports fail to
meet these criteria, and MSC is often employed for “marrow
stromal cell,” “mesenchymal stromal cell” or “marrow stem
cell.” Accordingly, a clariﬁcation was published in which
MSC was deﬁned as “multipotent mesenchymal stromal
Cells” [22], adding the supportive property to the required
characteristics [23].
3. What Do MSCs Have to Offer to
Cardiac Regeneration?
When considering the goal of cardiac tissue regeneration, the
desired objective must encompass three objectives: (i) the
productionofareplacementmyocardialmass,(ii)theforma-
tion of a functional vascular network to sustain it, and (iii)
the returning of the impaired ventricle to its proper geom-
etry. Cell therapy may theoretically aﬀect those processes
in two ways: either by direct diﬀerentiation of transplanted
cells towards the desired lineages or by their production of
molecules with therapeutic potential (Figure 1).
BM-MSC have shown their in vitro capacity to give
rise to endothelial cells (ECs) [24, 25] and smooth muscle
cells (SMCs) [24]. Cardiomyocyte diﬀerentiation has proved
more problematic, as either demethylating agents have been
employed [26], or it has been ineﬃcient and incomplete
[27, 28]. In contrast, the cardiac potential of ADSC is better
documented in vitro, showing their capacity to give rise to
CM, either by the use of DMSO [29]o rC Me x t r a c t s[ 30].
In addition, ADSC seems to harbor a progenitor subset
Table 1: Standardized requirements for MSC deﬁnition.
Multipotent mesenchymal stromal cells (MSE) properties
(i) Plastic adherence
(ii) Cell surface antigen expression proﬁle
CD73+,C D 9 0 +, CD105+,H L A - D R −, CD11b−,C D 1 4 −,
CD19−,C D 3 4 −,C D 4 5 −,C D 7 9 α−
(iii) Multipotency
Chondroblast, Adipocyte, Osteoblast
characterized by the expression of Nkx2.5 and Mcl2v [31]
and whose diﬀerentiation relies on the autocrine/paracrine
activity of vascular endothelial growth factor (VEGF) [32].
SMC [33]a n dE C[ 34] have been obtained from adipose
cells, yet a cautionary note must be struck, as some of these
studies either rely on subpopulations of freshly isolated cells
orculturethemindiﬀerentiation-promotingmediumbefore
purifying the mesenchymal population [35, 36]. Finally,
other mesenchymal progenitors have also been diﬀerentiated
to CM or CM-like cells, such as menstrual blood-derived
MSC [18] or umbilical cord blood MSC [37].
However, although it is extremely interesting, this dif-
ferentiation potential must cope with two opposing fac-
tors. First, patients receiving stem cell therapy are severely
diseased and usually elderly, two factors that have an
outstanding impact on stem cell function. For instance, a
decrease in the numbers and functionality of circulating
endothelial progenitors is directly related to cardiovascular
risks and smoking [38, 39] and age has also been shown
to impair the angiogenic capacity of both ADSC [40]a n d
BM-MSC [41]. Second, the small percentage of engrafted
cells (see [42] for a review) coupled to the huge catastrophe
caused by an MI (the loss in some cases of over 1 billion CM
[43]) and the low rate of diﬀerentiation achieved even under
in vitro controlled conditions makes the adding of such small
number of cells a therapeutically ineﬃcient approach.
Nevertheless, secretion of beneﬁcial molecules has been
demonstrated to be able to exert a positive eﬀect, even
when a few engrafted cells are left [44]. These molecules
can induce a beneﬁt either by increasing tissue perfusion,
decreasing collagen deposition and ﬁbrosis, enhancing host-
cell survival, or attracting/regulating endogenous progeni-
tors. Thus, Chen and coworkers compared the expression
proﬁle of BM-MSC and dermal ﬁbroblasts [45], showing
that mesenchymal progenitors secreted a higher amount
of several molecules, including the potent proangiogenic
cytokine VEGF or the chemotactic stromal derived factor-
1 (SDF-1). Conditioned medium from BM-MSC induced
the recruitment of EC and macrophages, and improved
wound healing. Moreover, it has recently been shown that
serum-deprived BM-MSC acquire EC features and increase
the release of VEGF or hepatocyte growth factor (HGF),
another potent angiogenic molecule [46], both of which
have been reported to be secreted by ADSC [32, 47, 48].
Moreover, Dr. March’s group demonstrated that ADSCs
have a pericytic nature and are able to form and stabilize
functional vascular networks when mixed with endothelialStem Cells International 3
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MSC diﬀerentiation paracrine MSC eﬀect
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￿ Proangiogenic: VEGF, HGF
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Figure 1: Main MSC actions on injured myocardium. Mesenchymal progenitors transplanted onto the ischemic myocardium are able to
secrete a plethora of therapeutic molecules (paracrine activity) and even to diﬀerentiate towards (cardio-) vascular lineages, encouraging
the healing of the damaged tissue, avoiding its transition to a scarred muscle, and regenerating the heart tissue mainly at the vascular
level. Abbreviations: IGF-1: insulin-like growth factor-1; SDF-1: stromal derived factor-1; VEGF: vascular endothelial growth factor; HGF:
hepatocyte growth factor; MMP: matrix metalloproteinase; LV: left ventricle.
progenitors [49]. Also, BM-MSC show a potent antiﬁbrotic
action, as their conditioned medium decreases cardiac
ﬁbroblastproliferationandexpressionofcollagentypesIand
III [50, 51] and increases secretion of antiﬁbrotic molecules
such as matrix metalloproteinases (MMPs) 2, 9, and 14 [52].
These cells express ﬁve types of MMP (2, 13 and membrane
type-MMP 1, 2, and 3) and are able to cross through type
I collagen membranes [53], which theoretically would allow
their traﬃcking across the infarction-derived scar. Likewise,
ADSCs produce transforming growth factor- (TGF-) β1
[54], a potent regulator of ﬁbrosis. Taken as a whole, these
examples demonstrate that mesenchymal progenitors are
potent paracrine mediators with a considerable capacity to
impact infarct evolution.
One last noteworthy competence is the ability of BM-
MSCandADSCtomodulatetheimmuneresponse.Marrow-
derived mesenchymal progenitors inhibit the proliferation
of activated T cells and the formation of cytotoxic T
cells [55], inducing an anti-inﬂammatory phenotype, which
would allow their allogenic use and signiﬁcantly broaden the
scope of their applicability. However, Huang et al. reported
that diﬀerentiation reduced their capacity of immunological
escape [56], related to an increase of immunostimulatory
molecules MHC-Ia and II and a decrease in the immuno-
suppressive MHCIb. Along similar lines, McIntosh and
coworkersreportedthatADCSbeyondpassageone(andthus
devoid of contaminating diﬀerentiated cells [57]) failed to
elicit a response from allogenic T cells [58], but this attribute
may be diminished under inﬂammatory stimuli, as shown in
vitro [59].
Finally, since the onset of induced pluripotent stem cells
(iPSCs) [60], mesenchymal cells have been investigated [61,
62] due to their relatively easy harvest and higher potency
than other cell types (e.g., dermal ﬁbroblasts), which show
anincreasedeﬃciency,evenintheabsenceoftheoncogenec-
Myc. Their supportive capacities have also made them good
candidates to replace mouse cells as feeders [63, 64].
4.MSC inAnimalModels ofMI
However, in spite of all the positive characteristics of
mesenchymal progenitors already depicted, their in vivo
testing in animal models of the disease is compulsory. In
this regard, three diﬀerent settings can be found. First, the
acute setting, in which cells are transplanted within hours of
the MI. Here, the inﬂammatory microenvironment and the
necrotic/apoptotic signals released from resident cells [65,
66] are the main opposing forces to the therapeutic activity
of cells. Nevertheless, homing signals [67] and an antiﬁbrotic
milieu [68] may have a positive inﬂuence. Also, from a
practical point of view, dealing with acute models oﬀers the
advantage of subjecting animals to only one surgery, as at the
time of the MI (or minutes afterit), the cells are applied, thus
decreasing mortality and invasiveness. As a consequence, the
majority of published reports use acute models [37, 69–
84]. Most studies (with the exception of the two by van der
Bogtandcolleagues[74,77])haveconsistentlydemonstrated
that the treatment induces a signiﬁcant beneﬁt for cardiac
function, mainly through paracrine mechanisms that induce
an increase in tissue perfusion and a decrease in the size of
the scar and collagen content.4 Stem Cells International
Similarresultshavebeenobtainedinasecondsetting,the
chronic one. Here, the repair processes that take place after
ischemia have been completed, the scar has matured, and
although a new network of blood vessels has been created,
this is disorganized and inadequate [85, 86]. These facts
i m p o s eag r e a tb u r d e nu p o nc e l ls u r v i v a l .H o w e v e r ,i tm u s t
be taken into account that the generation of homogeneous
populations as BM-MSC or ADSC needs weeks of in vitro
culture, thus, unless used in the allogeneic setting, there
is no possibility of the bedside translation of the use of
mesenchymal progenitors in the acute setting. In spite of
this diﬃculty, fewer reports deal with this issue [87–90].
Compared to results in the acute setting, mesenchymal cell
therapy of chronically infarcted hearts has a positive eﬀect
upon organ contractility and histology.
As a third and intermediate position, the so-called suba-
cute model represents a situation where angiogenic processes
are still on course, either through endothelial progenitors
[91]o rm a c r o p h a g e s[ 92], and the receding of inﬂammation
plus the increase in ﬁbrotic processes are also on course. As
with chronic models, there are few reports in this setting
[17,18,93,94],butagainthebeneﬁtandmechanismsappear
to be consistent.
Nevertheless, analyzing in more depth the studies men-
tioned above, it is possible to ﬁnd a fair amount of
information on how mesenchymal progenitors behave when
injected into the diseased heart has been gathered. Chen
et al. showed that transplantation of BM-MSC into chron-
ically infarcted rabbit hearts induced an increase in the
concentration of SDF-1 that elicited the chemotaxis of host-
derivedBMprogenitors(CD34+,CD117+,STR O1 +)andwas
related to a functional beneﬁt, a decrease in infarct size and
improvementintissuevascularization[89].Liandcoworkers
demonstrated that the functional enhancement was accom-
panied by the augmented expression of the prosurvival gene
Akt[95]whereasMiasandcolleaguesshowedthatthebeneﬁt
upon contractility and remodeling in vivo was accompanied
in vitro by a plethora of antiﬁbrotic actions [52]. In a
sheep model of MI, the group of Dr. Spinale monitored
the evolution of MMP and their inhibitors, demonstrating
a relationship with the number of transplanted cells [75].
Resembling their in vitro behavior, several publications have
demonstratedtheassociationbetweenproangiogenicactivity
in vitro and secretion (either direct or host-derived) of
angiogenic cytokines as VEGF, HGF, or insulin-like growth
factor-1 (IGF-1), among others [17, 84, 93, 96, 97]. Whether
these capacities are related to the claimed pericytic nature of
these cells [10, 48, 49] remains to be resolved.
Immune modulation (reviewed in [98]) in theory pro-
vides the means for the allogenic use of MSCs and as an
oﬀ-the-shelf product (expanded prior to the onset of the
ischemia and applicable on demand). Two reports have
compared the eﬀects of allogenic versus syngenic injection
of BM-MSC in rat model of MI, with conﬂicting results.
Imanishi et al. [78] demonstrated that both autologous and
allogeneic cells improved cardiac function 4 weeks after
transplantation, remained in the damaged tissues, and did
not stimulate rejection. Huang and coworkers conversely
[56] followed animals for up to 6 months. Syngenic cells
stimulated cardiac recovery, but the eﬀect of the allogenic
treatmentwastransitory(signiﬁcant3monthsafterinjection
but not at 6) and BM-MSC disappeared earlier than
their syngenic counterpart. However, this diﬀerence can be
attributed to methodological discrepancies regarding time
of transplantation (acute versus chronic resp.) or followup
(1 versus 6 months). Equivalent and importantly, results
from clinically relevant large animal models of MI in which
allogenic cells have been employed have revealed either
positive[99,100]ornofunctionalout c ome[79].Incontrast,
when autologous ADSC or BM-MSC are used [72, 83,
101, 102], reports have shown a robust and consistent
functional recovery after cell transplantation. Thus, strict
considerations about building up animal models must be
taken into account.
5. Problems, Solutions
Despite all the optimism, stem cell therapy shows certain
caveats that are amenable to improvement, namely, lack
of substantial engraftment and cell persistence, high levels
of death, and low in vivo diﬀerentiation capacity. Some
approaches to try to remedy these problems have included
the use of genetic manipulation and in vitro pretreatment
of cells or biomaterials. In this sense, the CXCR4/SDF-1
axis has been greatly exploited. Ma et al. investigated the
peak of cardiac SDF-1 expression [103] in rat MI, ﬁnding
that injected cells at that time point (1 day postinfarction)
increased cell engraftment and tissue angiogenesis. Cheng
and coworkers transplanted BM-MSC engineered to over-
express the receptor CXCR4, strengthening cell homing to
the injured tissue after tail vein injection [104]. The same
group combined BM-MSC peripheral injection with admin-
istration of granulocyte colony-stimulating factor, which
in vitro increased CXCR4 expression. However, although
engraftment was increased, no eﬀect of cardiac function was
found [105]. Huang and associates demonstrated that over-
expression of the chemokine receptor CCR1 but not CXCR2
was associated with improved survival and grafting in a
mouse model of MI, which also restored functionality [106].
Cell survival in the infarcted myocardium is jeopar-
dized by hypoxia, inﬂammation, or oxidative stress. Liu et
al. engineered BM-MSC to overexpress angiogenin [107],
which improved hypoxic resistance in culture and was
translatedintoanincreaseincellengraftmentandfunctional
and histological recovery induction. Cell overexpression of
hemeoxygenase-1 through adenoviral transfection showed
superior therapeutic capacity, mainly through protection
from inﬂammation and apoptosis [108], whereas targeted
Akt overproduction in MSC restored cardiac function 2
weeks after MI through paracrine actions, including protec-
tion from hypoxia-induced apoptosis, release of cytokines,
and preservation of tissue metabolism [109–111]. Others
have explored antioxidants, like Song et al. who published
that reactive oxygen species (ROS) diminished BM-MSC
adherence to the substrate, but when treated with an ROS
scavenger (N-acetyl-L-cysteine), engraftment was improved
and the increase in ﬁbrosis and infarct size prevented [112].Stem Cells International 5
Hsp20 overexpression also protected MSC from oxidative
stress and improved their beneﬁcial activities [97].
However, viral or genetic modiﬁcation of cells implies
certain risks that currently make it diﬃcult for a devised
therapy to reach the bedside. Bioengineering uses biocom-
patible materials to improve or direct cell therapy and either
synthetic or naturally derived systems have been employed.
Jin and coworkers seeded BM-MSC on poly(lactide-co-1-
caprolactone) patches which when applied on a rat cry-
oinjury model were able to improve cardiac function and
decrease infarct size [113]. Porcine small intestine sub-
mucosa, a decellularized substrate, has been employed to
treat a rabbit model of chronic MI, showing a signiﬁcant
beneﬁt upon contractility and histology, as well as cell
migration towards the injured tissue [114]. The cell sheet
technology allows increasing thickness through stacking
of constructs, as shown by Chen et al. [115], where its
transplantation in a rat syngenic model of cardiac ischemia
improved cardiac function as well as paracrine secretion
of therapeutic molecules by grafted cells. Dr. Mori’s group
compared the transplantation of a cell sheet seeded with
ADSC versus ﬁbroblasts, showing the superior eﬀect of
the mesenchymal progenitors [116]. Recently, autologous
ADSC were transplanted along with allogenic ESC-derived
CD15+ cardiac progenitors in a monkey model of infarction,
demonstrating the safety of the procedure, although the
functional outcome was not analyzed [117].
Finally, a word of caution must be added. Animal models
ofthediseaseareapowerfultooltoexplorethefeasibilityofa
certain therapy, as MSC treatment of MI, but despite positive
and reproducible results, rodent and even large animal
models are just oversimpliﬁcations of the more complex
setting of the human disease. As above stated, animals where
cell therapy is applied are not elderly, nor severely diseased,
thus making any result, even if tremendously positive, just
a clue or hint before proceeding to the ﬁnal application
to patients, where the real safety and eﬀectiveness can be
assessed.
6. Mesenchymal Progenitorsand
ClinicalApplication
Several clinical trials have been performed with autologous
BM-MSC, proving their safety when transplanted in patients
with either acute or chronic myocardial infarction [118–
120]. Moreover, the ﬁrst clinical trial designed as a ran-
domized study showed an improvement in the cardiac func
tion 3 months after BM-MSC intracoronary infusion in
patients with acute MI [120]. In view of the encouraging
results of the previous clinical trials, new phase-I/II studies
have been initiated, including the transendocardial au-
tologous cells (hMSC or hBMC) in Ischemic Heart
Failure Trial (TAC-HFT; http://www.clinicaltrials.org/
NCT00768066/), the Prospective Randomised study Of
MSC THErapy in patients Undergoing cardiac Surgery
(PROMETHEUS) trial (http://www.clinicaltrials.org/
NCT00587990/), and the Percutaneous Stem Cell Injection
DeliveryEﬀectsonNeomyogenesis(POSEIDON)pilotstudy
(http://www.clinicaltrials.org/NCT01087996/)[ 121], among
others.
BM-MSCs from allogeneic origin have been tested as
an oﬀ-the-shelf cell product. The ﬁrst phase-I, randomized,
double-blind, placebo-controlled, dose-escalation study was
performed in 53 patients with acute MI, who intravenously
received one of three doses of BM-MSCs (0.5, 1.6 or 5.0 ×
106 BM-MSC/Kg body weight) derived from a single cell
donor (Prochymal; Osiris therapeutics, Inc.) or placebo
[122]. Safety of the procedure was proven, showing fewer
episodes of ventricular tachycardia and even a better lung
function in the cell-treated group. Also, renal, hepatic, and
hematologic laboratory indexes were similar in the two
groups and no patient developed tumors. Importantly, a
signiﬁcant increase was detected in the ejection fraction
(EF) of the treated patients. In a magnetic resonance
imaging substudy, cell treatment, but not placebo, increased
left ventricular ejection fraction and led to a reversal of
adverse remodeling after 6 months of treatment. Now, a
phase-II multicentre trial of ProchymalTM has been started
(http://www.clinicaltrials.org/NCT00877903/).
Furthermore, BM-MSC safety has been tested in patients
with moderate-to-severe chronic heart failure in a phase-II,
randomized, single-blind, placebo-controlled, dose-escala-
tion, multicenter study. In this clinical trial, the patients
received an endoventricular injection of an allogeneic
BM-MSC product (Revascor, Mesoblast Ltd.) along the
infarct border zone and no procedure-related complications
were reported. Analysis of the data obtained after 6 months
of followup (http://www.mesoblast.com/newsroom/asx-
announcements/archives/) showed a signiﬁcant decrease
in the number of patients who developed any severe or
major adverse cardiac event, such as composite of cardiac
death, heart attack, or need for coronary revascularization
procedures. Moreover, the ﬁrst cohort in the study (n = 20
patients), which received the low dose of the cell treatment,
showed a signiﬁcantly greater increase in the EF when
compared with the control group [123].
On the other hand, regarding other sources of MSC
such as adipose tissue, no clinical trials have been ini-
tiated yet, despite the fact that the beneﬁcial potential
of ADSC has been preclinically demonstrated [83]. Until
now, only the noncultured adipose stromal vascular frac-
tion is being tested at the clinical level. The ﬁrst study,
a double-blind, placebo-controlled trial named APOLLO
(http://www.clinicaltrials.org/NCT00442806/;[ 124]) where
AMI patients received autologous adipose derived stem cells
by intracoronary infusion, was proven safe. Now, a phase
II/III ADVANCE trial has been initiated to evaluate their
eﬃcacy (http://www.clinicaltrials.org/NCT01216995/).
In general, the results obtained from the many clinical
trials performed, either with MSC or other stem cell popula-
tions (mainly BM-derived cells and skeletal myoblasts), have
taught us several important lessons that will help to design
and interpret the following clinical trials. (i) Cell treatment
is not equally eﬃcacious in all the patients. In general, it
seems that the worse the heart damage (meaning severely
decreased postrevascularization LVEF or high degree of
infarct transmurality), the better the beneﬁt induced by the6 Stem Cells International
transplanted cells seems to be [125–127]. (ii) Cell dose and
timing for treatment are critical. Thus, a meta-analysis of the
resultsobtainedinthemostrelevantclinicaltrialsperformed
in acute MI patients treated with BM cells has shown a
signiﬁcantly greater eﬀect in those patients that received
high cell doses (108 cells). Also, the same study showed a
greater beneﬁcial eﬀect when cells are infused during the
ﬁrst week after the infarct [128]. (iii) Autologous treatment
is not necessarily the best. Until now, most of the clinical
studies have been designed for autologous cell application
in order to avoid the immunorejection of the transplanted
cells. However, it has to be borne in mind that stem cells
derived from aged patients with risk of atherosclerosis or
other diseases might be defective, and thereby, treatment
with them might not be as eﬃcacious as with cells derived
from young healthy donors [129–131]. In that sense, the
use of MSC, which present immunomodulatory properties
[132], could be of great relevance. Thus, advantages of
allogeneic MSC treatment would be that, together with the
putative greater paracrine eﬀect that allogeneic cells derived
from a healthy donor could exert, a fully tested clinical grade
ready to use allogeneic cell product could be available for
any patient. Importantly, patients with acute MI could also
be eligible for such treatment. Furthermore, the logistical
complexity and manufacturing costs that autologous cell
preparation implies would be signiﬁcantly reduced by the
allogeneic application. However, caution should be taken
when taking into consideration the issues related to their
immune privilege explained above.
Thus, although it is mandatory to better understand the
mechanisms involved in the MSC phenotype switch and to
elucidate how this could aﬀect the cells’ potential beneﬁt, it
has to be considered that, in any case, because MSC would
not diﬀerentiate towards cardiovascular cells and would act
as a paracrine factor source [111], their permanent presence
in the heart might not be necessary for therapeutic purposes.
In that case, a temporarily action should be suﬃcient for
exerting their beneﬁt. Phase-II clinical trials are currently
assessing the eﬃcacy of the allogeneic MSC treatment,
together with the long-term safety. If allogeneicity of the
cells diminishes their eﬀectiveness, several options could
be considered, like temporal patient immunosuppression
and/or donor-recipient HLA-II mismatch minimizing. As
a consequence, the increase in the rate of engraftment of
transplanted cells is so far one of the main challenges. As
already indicated, the use of scaﬀolds could improve this
factor. Interestingly, a clinical trial has been performed in 15
patients with chronic MI who were treated with a collagen
scaﬀold previously seeded with bone marrow mononuclear
cells [133]. The cellularized patch was implanted onto the
pericardium and no adverse events were reported, showing
the feasibility and safety of the treatment. Furthermore,
a limiting eﬀect in ventricular wall remodeling and an
improved diastolic function were detected. These posi-
tive results will probably promote new larger randomized
controlled trials, where mesenchymal and other stem cell
populations might be tested in combination with scaﬀolds,
thus leading to a further step in the therapeutic use of stem
cells.
7. Conclusion
Mesenchymal cells have raised substantial interest in recent
years due to their potential and versatility. Although we are
only now starting to understand the mechanisms by which
they repair or induce the repair of damaged organs, their
pleiotropic activity and the technical ease of manipulation
makes them good candidates for the treatment of the MI.
Though waiting for randomized, double-blinded, placebo-
controlled clinical trials in which large cohorts of patients
could participate, the available data demonstrates the safety
of the therapy and points towards a positive eﬀect, further
encouraging new investigations. The addition of the latest
improvements in the ﬁeld, including in vitro conditioning
and bioengineering, will surely suppose a further step
towards ﬁnding an optimized treatment. However, certain
issues, mainly immunomodulatory capacity and allogenic
use, need to be better understood.
Acknowledgments
This work was supported by grants to FP (FP7 INELPY,
Instituto de Salud Carlos III (ISCIII-RETIC RD06/0014
(FIS)) and Ministero de Ciencia e Innovaci´ on Programa de
Internacionalizaci´ on CARDIOBIO) and BP (Instituto de Sa-
lud Carlos III (PI10/01621 and CP09/00333 (FIS)).
References
[1] World Health Organization, World Health Statistics 2008,
2008.
[2] M. Mazo, B. Pelacho, and F. Pr´ osper, “Stem cell therapy
for chronic myocardial infarction,” Journal of Cardiovascular
Translational Research, vol. 3, no. 2, pp. 79–88, 2010.
[3] N. G. Frangogiannis, “Chemokines in the ischemic my-
ocardium: from inﬂammation to ﬁbrosis,” Inﬂammation
Research, vol. 53, no. 11, pp. 585–595, 2004.
[4] A. J. Friedenstein, K. V. Petrakova, A. I. Kurolesova, and
G. P. Frolova, “Heterotopic of bone marrow. Analysis of
precursor cells for osteogenic and hematopoietic tissues,”
Transplantation, vol. 6, no. 2, pp. 230–247, 1968.
[5] B. Pelacho and F. Prosper, “Stem cells and cardiac disease:
where are we going?” C u r r e n tS t e mC e l lR e s e a r c h&T h e r a p y ,
vol. 3, no. 4, pp. 265–276, 2008.
[6] C. Clavel and C. M. Verfaillie, “Bone-marrow-derived cells
and heart repair,” Current Opinion in Organ Transplantation,
vol. 13, no. 1, pp. 36–43, 2008.
[7] T. Walenda, S. Bork, P. Horn et al., “Co-culture with mes-
enchymal stromal cells increases proliferation and mainte-
nance of haematopoietic progenitor cells,” Journal of Cellular
and Molecular Medicine, vol. 14, no. 1-2, pp. 337–350, 2010.
[8] D. L. Jones and A. J. Wagers, “No place like home: anatomy
and function of the stem cell niche,” Nature Reviews Molecu-
lar Cell Biology, vol. 9, no. 1, pp. 11–21, 2008.
[9] W. Wagner, C. Roderburg, F. Wein et al., “Molecular and
secretory proﬁles of human mesenchymal stromal cells and
their abilities to maintain primitive hematopoietic progeni-
tors,” Stem Cells, vol. 25, no. 10, pp. 2638–2647, 2007.
[10] X. Cai, Y. Lin, C. C. Friedrich et al., “Bone marrow derived
pluripotent cells are pericytes which contribute to vascular-
ization,” Stem Cell Reviews and Reports, vol. 5, no. 4, pp. 437–
445, 2010.Stem Cells International 7
[11] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage
potential of adult human mesenchymal stem cells,” Science,
vol. 284, no. 5411, pp. 143–147, 1999.
[ 1 2 ]M .M a z o ,J .J .G a v i r a ,B .P e l a c h o ,a n dF .P r o s p e r ,“ A d i p o s e -
derived stem cells for myocardial infarction,” Journal of
Cardiovascular Translational Research, vol. 4, no. 2, pp. 145–
153, 2011.
[13] L. Casteilla, V. Planat-Benard, P. Laharrague, and B. Cousin,
“Adipose-derived stromal cells: their identity and uses in
clinical trials, an update,” World Journal of Stem Cells, vol. 3,
pp. 25–33, 2011.
[ 1 4 ]S .K e r n ,H .E i c h l e r ,J .S t o e v e ,H .K l u t e r ,a n dK .B i e b a c k ,
“Comparative analysis of mesenchymal stem cells from bone
marrow, umbilical cord blood, or adipose tissue,” Stem Cells,
vol. 24, no. 5, pp. 1294–1301, 2006.
[15] J. M. Gimble, A. J. Katz, and B. A. Bunnell, “Adipose-derived
stem cells for regenerative medicine,” Circulation Research,
vol. 100, no. 9, pp. 1249–1260, 2007.
[16] S. E. Yang, C. W. Ha, M. H. Jung et al., “Mesenchymal
stem/progenitor cells developed in cultures from UC blood,”
Cytotherapy, vol. 6, no. 5, pp. 476–486, 2004.
[17] C. Gandia, A. N.A. Armi˜ nan, J. M. Garc´ ıa-Verdugo et al.,
“Human dental pulp stem cells improve left ventricular
function, induce angiogenesis, and reduce infarct size in rats
with acute myocardial infarction,” Stem Cells, vol. 26, no. 3,
pp. 638–645, 2008.
[18] N. Hida, N. Nishiyama, S. Miyoshi et al., “Novel cardiac
precursor-like cells from human menstrual blood-derived
mesenchymal cells,” Stem Cells, vol. 26, no. 7, pp. 1695–1704,
2008.
[19] S. Carlson, J. Trial, C. Soeller, and M. L. Entman, “Cardiac
mesenchymal stem cells contribute to scar formation after
myocardial infarction,” Cardiovascular Research, vol. 91, no.
1, pp. 99–107, 2011.
[20] D. C. Ding, W. C. Shyu, and S. Z. Lin, “Mesenchymal stem
cells,” Cell Transplant, vol. 20, pp. 5–14, 2011.
[21] M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal
criteria for deﬁning multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position
statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.
[22] E. M. Horwitz, K. Le Blanc, M. Dominici et al., “Clariﬁcation
of the nomenclature for MSC: the international society for
cellular therapy position statement,” Cytotherapy, vol. 7, no.
5, pp. 393–395, 2005.
[23] B. Sacchetti, A. Funari, S. Michienzi et al., “Self-renewing
osteoprogenitors in bone marrow sinusoids can organize a
hematopoietic microenvironment,” Cell, vol. 131, no. 2, pp.
324–336, 2007.
[ 2 4 ]T .P .L o z i t o ,J .M .T a b o a s ,C .K .K u o ,a n dR .S .T u a n ,
“Mesenchymal stem cell modiﬁcation of endothelial matrix
regulates their vascular diﬀerentiation,” Journal of Cellular
Biochemistry, vol. 107, no. 4, pp. 706–713, 2009.
[25] J. W. Liu, S. Dunoyer-Geindre, V. Serre-Beinier et al.,
“Characterization of endothelial-like cells derived from
human mesenchymal stem cells,” Journal of Thrombosis and
Haemostasis, vol. 5, no. 4, pp. 826–834, 2007.
[ 2 6 ]W .X u ,X .Z h a n g ,H .Q i a ne ta l . ,“ M e s e n c h y m a ls t e m
cells from adult human bone marrow diﬀerentiate into a
cardiomyocytephenotypeinvitro,”ExperimentalBiologyand
Medicine, vol. 229, no. 7, pp. 623–631, 2004.
[27] X. Yan, A. Lv, Y. Xing et al., “Inhibition of p53-p21 pathway
promotes the diﬀerentiation of rat bone marrow mesenchy-
mal stem cells into cardiomyocytes,” Molecular and Cellular
Biochemistry, vol. 354, no. 1-2, pp. 21–28, 2011.
[28] A. Armi˜ n´ an, C. Gand´ ı a ,J .M .G a r c ´ ıa-Verdugo et al., “Cardiac
transcription factors driven lineage-speciﬁcation of adult
stem cells,” Journal of Cardiovascular Translational Research,
vol. 3, no. 1, pp. 61–65, 2010.
[29] A. van Dijk, H. W. M. Niessen, B. Zandieh Doulabi,
F .C .V i s s e r ,a n dF .J .V a nM i l l i g e n ,“ D i ﬀerentiation of
human adipose-derived stem cells towards cardiomyocytes is
facilitated by laminin,” Cell and Tissue Research, vol. 334, no.
3, pp. 457–467, 2008.
[30] K. G. Gaustad, A. C. Boquest, B. E. Anderson, A. M. Gerdes,
and P. Collas, “Diﬀerentiation of human adipose tissue stem
cells using extracts of rat cardiomyocytes,” Biochemical and
Biophysical Research Communications, vol. 314, no. 2, pp.
420–427, 2004.
[31] X. Bai, K. Pinkernell, Y. H. Song, C. Nabzdyk, J. Reiser, and
E. Alt, “Genetically selected stem cells from human adipose
tissue express cardiac markers,” Biochemical and Biophysical
Research Communications, vol. 353, no. 3, pp. 665–671, 2007.
[ 3 2 ]Y .H .S o n g ,S .G e h m e r t ,S .S a d a te ta l . ,“ V E G Fi sc r i t i c a l
for spontaneous diﬀerentiation of stem cells into cardiomy-
ocytes,” Biochemical and Biophysical Research Communica-
tions, vol. 354, no. 4, pp. 999–1003, 2007.
[ 3 3 ]Y .M .K i m ,E .S .J e o n ,M .R .K i m ,S .K .J h o ,S .W .R y u ,a n d
J. H. Kim, “Angiotensin II-induced diﬀerentiation of adipose
tissue-derivedmesenchymalstemcellstosmoothmuscle-like
cells,” International Journal of Biochemistry and Cell Biology,
vol. 40, no. 11, pp. 2482–2491, 2008.
[34] V. Planat-Benard, J. S. Silvestre, B. Cousin et al., “Plasticity
of human adipose lineage cells toward endothelial cells:
physiological and therapeutic perspectives,” Circulation, vol.
109, no. 5, pp. 656–663, 2004.
[35] L. J. Fischer, S. McIlhenny, T. Tulenko et al., “Endothe-
lial diﬀerentiation of adipose-derived stem cells: eﬀects of
endothelial cell growth supplement and shear force,” Journal
of Surgical Research, vol. 152, no. 1, pp. 157–166, 2009.
[36] C. Sengen` es, A. Miranville, M. Maumus, S. De Barros, R.
Busse,andA.Bouloumi´ e,“Chemotaxisanddiﬀerentiationof
humanadiposetissueCD34+/CD31-progenitorcells:roleof
stromal derived factor-1 released by adipose tissue capillary
endothelial cells,” Stem Cells, vol. 25, no. 9, pp. 2269–2276,
2007.
[37] S.A.Chang,J.L.Eun,H.J.Kangetal.,“Impactofmyocardial
infarctproteinsandoscillatingpressureonthediﬀerentiation
of mesenchymal stem cells: eﬀect of acute myocardial infarc-
tion on stem cell diﬀerentiation,” Stem Cells, vol. 26, no. 7,
pp. 1901–1912, 2008.
[38] T.Kondo,M.Hayashi,K.Takeshitaetal.,“Smokingcessation
rapidly increases circulating progenitor cells in peripheral
blood in chronic smokers,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 24, no. 8, pp. 1442–1447, 2004.
[39] M. Vasa, S. Fichtlscherer, A. Aicher et al., “Number and
migratory activity of circulating endothelial progenitor cells
inversely correlate with risk factors for coronary artery
disease,” Circulation research, vol. 89, no. 1, pp. E1–7, 2001.
[40] R. Madonna, F. V. Renna, C. Cellini et al., “Age-dependent
impairment of number and angiogenic potential of adipose
tissue-derived progenitor cells,” European Journal of Clinical
Investigation, vol. 41, no. 2, pp. 126–133, 2011.
[41] H. Liang, H. Hou, W. Yi, G. Yang, C. Gu, W. B. Lau et al.,
“Increased expression of pigment epithelium-derived factor
in aged mesenchymal stem cells impairs their therapeutic
eﬃcacy for attenuating myocardial infarction injury,” Euro-
pean Heart Journal, In press.8 Stem Cells International
[42] H. K. Haider and M. Ashraf, “Strategies to promote donor
cell survival: combining preconditioning approach with
stem cell transplantation,” Journal of Molecular and Cellular
Cardiology, vol. 45, no. 4, pp. 554–566, 2008.
[43] T. E. Robey, M. K. Saiget, H. Reinecke, and C. E. Murry,
“Systems approaches to preventing transplanted cell death in
cardiac repair,” Journal of Molecular and Cellular Cardiology,
vol. 45, no. 4, pp. 567–581, 2008.
[44] P. W. M. Fedak, “Paracrine eﬀects of cell transplantation:
modifying ventricular remodeling in the failing heart,”
Seminars in Thoracic and Cardiovascular Surgery, vol. 20, no.
2, pp. 87–93, 2008.
[45] L. Chen, E. E. Tredget, P. Y. G. Wu, Y. Wu, and Y. Wu,
“Paracrine factors of mesenchymal stem cells recruit ma-
crophages and endothelial lineage cells and enhance wound
healing,” PLoS ONE, vol. 3, no. 4, Article ID e1886, 2008.
[ 4 6 ]A .O s k o w i t z ,H .M c F e r r i n ,M .G u t s c h o w ,M .L .C a r t e r ,
and R. Pochampally, “Serum-deprived human multipotent
mesenchymal stromal cells (MSCs) are highly angiogenic,”
Stem Cell Research, vol. 6, no. 3, pp. 215–225, 2011.
[47] G. E. Kilroy, S. J. Foster, X. Wu et al., “Cytokine proﬁle of
human adipose-derived stem cells: expression of angiogenic,
hematopoietic, and pro-inﬂammatory factors,” Journal of
Cellular Physiology, vol. 212, no. 3, pp. 702–709, 2007.
[48] D. O. Traktuev, S. Merfeld-Clauss, J. Li et al., “A population
of multipotent CD34-positive adipose stromal cells share
pericyte and mesenchymal surface markers, reside in a
periendothelial location, and stabilize endothelial networks,”
Circulation Research, vol. 102, no. 1, pp. 77–85, 2008.
[49] D. O. Traktuev, D. N. Prater, S. Merfeld-Clauss et al.,
“Robust functional vascular network formation in vivo by
cooperation of adipose progenitor and endothelial cells,”
Circulation Research, vol. 104, no. 12, pp. 1410–1420, 2009.
[50] L. Li, S. Zhang, Y. Zhang, B. Yu, Y. Xu, and Z. Guan, “Par-
acrine action mediate the antiﬁbrotic eﬀect of transplanted
mesenchymalstemcellsinaratmodelofglobalheartfailure,”
Molecular Biology Reports, vol. 36, no. 4, pp. 725–731, 2009.
[51] S. Ohnishi, H. Sumiyoshi, S. Kitamura, and N. Nagaya,
“Mesenchymal stem cells attenuate cardiac ﬁbroblast prolif-
eration and collagen synthesis through paracrine actions,”
FEBS Letters, vol. 581, no. 21, pp. 3961–3966, 2007.
[52] C. Mias, O. Lairez, E. Trouche et al., “Mesenchymal stem
cells promote matrix metalloproteinase secretion by cardiac
ﬁbroblasts and reduce cardiac ventricular ﬁbrosis after
myocardial infarction,” Stem Cells, vol. 27, no. 11, pp. 2734–
2743, 2009.
[53] T. B. Rogers, S. Pati, S. Gaa et al., “Mesenchymal stem
cells stimulate protective genetic reprogramming of injured
cardiac ventricular myocytes,” Journal of Molecular and
Cellular Cardiology, vol. 50, no. 2, pp. 346–356, 2011.
[54] J. Rehman, D. Traktuev, J. Li et al., “Secretion of angiogenic
and antiapoptotic factors by human adipose stromal cells,”
Circulation, vol. 109, no. 10, pp. 1292–1298, 2004.
[55] S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem
cells modulate allogeneic immune cell responses,” Blood, vol.
105, no. 4, pp. 1815–1822, 2005.
[56] X. P. Huang, Z. Sun, Y. Miyagi et al., “Diﬀerentiation of
allogeneic mesenchymal stem cells induces immunogenicity
and limits their long-term beneﬁts for myocardial repair,”
Circulation, vol. 122, no. 23, pp. 2419–2429, 2010.
[57] J. B. Mitchell, K. McIntosh, S. Zvonic et al., “Immunophe-
notype of human adipose-derived cells: temporal changes in
stromal-associated and stem cell-associated markers,” Stem
Cells, vol. 24, no. 2, pp. 376–385, 2006.
[58] K. McIntosh, S. Zvonic, S. Garrett et al., “The immuno-
genicity of human adipose-derived cells: temporal changes in
vitro,” Stem Cells, vol. 24, no. 5, pp. 1246–1253, 2006.
[59] M. J. Crop, C. C. Baan, S. S. Korevaar et al., “Inﬂammatory
conditions aﬀect gene expression and function of human
adipose tissue-derived mesenchymal stem cells,” Clinical and
experimental immunology, vol. 162, no. 3, pp. 474–486, 2010.
[60] K. Takahashi and S. Yamanaka, “Induction of pluripotent
stem cells from mouse embryonic and adult ﬁbroblast
cultures by deﬁned factors,” Cell, vol. 126, no. 4, pp. 663–676,
2006.
[61] P. A. Tat, H. Sumer, K. L. Jones, K. Upton, and P. J. Verma,
“The eﬃcient generation of induced pluripotent stem (iPS)
cells from adult mouse adipose tissue-derived and neural
stem cells,” Cell Transplantation, vol. 19, no. 5, pp. 525–536,
2010.
[62] N. Sun, N. J. Panetta, D. M. Gupta et al., “Feeder-free
derivation of induced pluripotent stem cells from adult
human adipose stem cells,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 106,
no. 37, pp. 15720–15725, 2009.
[63] M. K. Mamidi, R. Pal, N. A.B. Mori et al., “Co-culture of
mesenchymal-likestromalcellsderivedfromhumanforeskin
permits long term propagation and diﬀerentiation of human
embryonic stem cells,” Journal of Cellular Biochemistry, vol.
112, no. 5, pp. 1353–1363, 2011.
[64] S. T. Hwang, S. W. Kang, S. J. Lee et al., “The expansion of
human ES and iPS cells on porous membranes and prolifer-
ating human adipose-derived feeder cells,” Biomaterials, vol.
31, no. 31, pp. 8012–8021, 2010.
[ 6 5 ]M .N i a n ,P .L e e ,N .K h a p e r ,a n dP .L i u ,“ I n ﬂ a m m a t o r y
cytokines and postmyocardial infarction remodeling,” Circu-
lation Research, vol. 94, no. 12, pp. 1543–1553, 2004.
[66] D. L. Mann, “Mechanisms and models in heart failure: a
combinatorial approach,” Circulation, vol. 100, no. 9, pp.
999–1008, 1999.
[67] M. S. Penn, “Importance of the SDF-1: CXCR4 axis in
myocardial repair,” Circulation Research, vol. 104, no. 10, pp.
1133–1135, 2009.
[68] J. P. M. Cleutjens, J. C. Kandala, E. Guarda, R. V. Guntaka,
and K. T. Weber, “Regulation of collagen degradation in the
rat myocardium after infarction,” Journal of Molecular and
Cellular Cardiology, vol. 27, no. 6, pp. 1281–1292, 1995.
[69] M. Ii, M. Horii, A. Yokoyama et al., “Synergistic eﬀect of
adipose-derived stem cell therapy and bone marrow progen-
itor recruitment in ischemic heart,” Laboratory Investigation,
vol. 91, no. 4, pp. 539–552, 2011.
[70] R. Gaebel, D. Furlani, H. Sorg et al., “Cell origin of human
mesenchymal stem cells determines a diﬀerent healing
performance in cardiac regeneration,” PLoS ONE, vol. 6, no.
2, Article ID e15652, 2011.
[71] X. Bai, Y. Yan, M. Coleman et al., “Tracking long-term sur-
vival of intramyocardially delivered human adipose tissue-
derived stem cells using bioluminescence imaging,” Molecu-
lar Imaging and Biology, pp. 1–13, 2010.
[72] C. Dubois, X. Liu, P. Claus et al., “Diﬀerential Eﬀects of Pro-
genitor Cell Populations on Left Ventricular Remodeling and
Myocardial Neovascularization After Myocardial Infarction,”
Journal of the American College of Cardiology, vol. 55, no. 20,
pp. 2232–2243, 2010.
[73] Y. J. Yang, H. Y. Qian, J. Huang et al., “Combined therapy
with simvastatin and bone marrow-derived mesenchymal
stem cells increases beneﬁts in infarcted swine hearts,”Stem Cells International 9
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no.
12, pp. 2076–2082, 2009.
[ 7 4 ]K .E .A .v a nd e rB o g t ,S .S c h r e p f e r ,J .Y ue ta l . ,“ C o m p a r i s o n
of transplantation of adipose tissue- and bone marrow-
derived mesenchymal stem cells in the infarcted heart,”
Transplantation, vol. 87, no. 5, pp. 642–652, 2009.
[75] J. A. Dixon, R. C. Gorman, R. E. Stroud et al., “Mesenchy-
mal cell transplantation and myocardial remodeling after
myocardial infarction,” Circulation, vol. 120, no. 1, pp. S220–
S229, 2009.
[76] X. Bai, Y. Yan, Y. H. Song et al., “Both cultured and freshly
isolated adipose tissue-derived stem cells enhance cardiac
function after acute myocardial infarction,” European Heart
Journal, vol. 31, no. 4, pp. 489–501, 2010.
[77] K. E. van der Bogt, A. Y. Sheikh, S. Schrepfer et al.,
“Comparison of diﬀerent adult stem cell types for treatment
of myocardial ischemia,” Circulation, vol. 118, no. 14, pp.
S121–129, 2008.
[78] Y. Imanishi, A. Saito, H. Komoda et al., “Allogenic mes-
enchymal stem cell transplantation has a therapeutic eﬀect
in acute myocardial infarction in rats,” Journal of Molecular
and Cellular Cardiology, vol. 44, no. 4, pp. 662–671, 2008.
[79] S. M. Hashemi, S. Ghods, F. D. Kolodgie et al., “A placebo
controlled,dose-ranging,safetystudyofallogenicmesenchy-
mal stem cells injected by endomyocardial delivery after an
acutemyocardialinfarction,”EuropeanHeartJournal,vol.29,
no. 2, pp. 251–259, 2008.
[80] S.L.Hale,W.Dai,J.S.Dow,andR.A.Kloner,“Mesenchymal
stemcelladministrationatcoronaryarteryreperfusioninthe
rat by two delivery routes: a quantitative assessment,” Life
Sciences, vol. 83, no. 13-14, pp. 511–515, 2008.
[81] C. A. Carr, D. J. Stuckey, L. Tatton et al., “Bone marrow-
derived stromal cells home to and remain in the infarcted
rat heart but fail to improve function: an in vivo cine-MRI
study,” American Journal of Physiology, Heart and Circulatory
Physiology, vol. 295, no. 2, pp. H533–H542, 2008.
[82] L. Cai, B. H. Johnstone, T. G. Cook et al., “IFATS collection:
human adipose tissue-derived stem cells induce angiogenesis
and nerve sprouting following myocardial infarction, in
conjunction with potent preservation of cardiac function,”
Stem Cells, vol. 27, no. 1, pp. 230–237, 2008.
[83] C. Valina, K. Pinkernell, Y. H. Song et al., “Intracoronary
administration of autologous adipose tissue-derived stem
cells improves left ventricular function, perfusion, and
remodelling after acute myocardial infarction,” European
Heart Journal, vol. 28, no. 21, pp. 2667–2677, 2007.
[84] B. Li, Q. Zeng, H. Wang et al., “Adipose tissue stromal
cells transplantation in rats of acute myocardial infarction,”
Coronary Artery Disease, vol. 18, no. 3, pp. 221–227, 2007.
[85] J. I. Virag and C. E. Murry, “Myoﬁbroblast and endothelial
cell proliferation during murine myocardial infarct repair,”
AmericanJournalofPathology, vol.163,no.6,pp.2433–2440,
2003.
[86] Y. Sun, M. F. Kiani, A. E. Postlethwaite, and K. T. Weber,
“Infarct scar as living tissue,” Basic Research in Cardiology,
vol. 97, no. 5, pp. 343–347, 2002.
[87] H.Song,M.J.Cha,B.W.Songetal.,“Reactiveoxygenspecies
inhibit adhesion of mesenchymal stem cells implanted into
ischemic myocardium via interference of focal adhesion
complex,” Stem Cells, vol. 28, no. 3, pp. 555–563, 2010.
[88] M. Mazo, J. J. Gavira, G. Abizanda et al., “Transplantation of
mesenchymal stemcells exerts a greater long-termeﬀectthan
bone marrow mononuclear cells in a chronic myocardial
infarction model in rat,” Cell Transplantation, vol. 19, no. 3,
pp. 313–328, 2009.
[89] M.F .Chen,B.C.Lee,H.C.Hsuetal.,“ Celltherapygenerates
a favourable chemokine gradient for stem cell recruitment
into the infarcted heart in rabbits,” European Journal of Heart
Failure, vol. 11, no. 3, pp. 238–245, 2009.
[90] M. Mazo, V. Planat-B´ enard, G. Abizanda et al., “Transplan-
tation of adipose derived stromal cells is associated with
functionalimprovementinaratmodelofchronicmyocardial
infarction,” European Journal of Heart Failure,v o l .1 0 ,n o .5 ,
pp. 454–462, 2008.
[91] K. Jujo, M. Ii, and D. W. Losordo, “Endothelial progenitor
cells in neovascularization of infarcted myocardium,”Journal
of Molecular and Cellular Cardiology, vol. 45, no. 4, pp. 530–
544, 2008.
[92] M. Nahrendorf, F. K. Swirski, E. Aikawa et al., “The healing
myocardium sequentially mobilizes two monocyte subsets
with divergent and complementary functions,” Journal of
ExperimentalMedicine,vol.204,no.12,pp.3037–3047,2007.
[93] L. Wang, J. Deng, W. Tian et al., “Adipose-derived stem cells
are an eﬀective cell candidate for treatment of heart failure:
an MR imaging study of rat hearts,” American Journal of
Physiology, Heart and Circulatory Physiology, vol. 297, no. 3,
pp. H1020–H1031, 2009.
[94] L. C. Amado, A. P. Saliaris, K. H. Schuleri et al., “Cardiac
repair with intramyocardial injection of allogeneic mes-
enchymal stem cells after myocardial infarction,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 102, no. 32, pp. 11474–11479, 2005.
[95] H. Li, D. Malhotra, C. C. Yeh et al., “Myocardial survival
signaling in response to stem cell transplantation,” Journal of
the American College of Surgeons, vol. 208, no. 4, pp. 607–613,
2009.
[96] J. Cho, P. Zhai, Y. Maejima, and J. Sadoshima, “Myocardial
injection with GSK-3β-overexpressing bone marrow-derived
mesenchymal stem cells attenuates cardiac dysfunction after
myocardial infarction,” Circulation Research, vol. 108, no. 4,
pp. 478–489, 2011.
[97] X. Wang, T. Zhao, W. Huang et al., “Hsp20-engineered
mesenchymal stem cells are resistant to oxidative stress via
enhancedactivationofAktandincreasedsecretionofgrowth
factors,” Stem Cells, vol. 27, no. 12, pp. 3021–3031, 2009.
[98] K. Le Blanc, “Mesenchymal stromal cells: tissue repair and
immunemodulation,”Cytotherapy,vol.8,no.6,pp.559–561,
2006.
[99] K.H.Schuleri,L.C.Amado,A.J.Boyleetal.,“Earlyimprove-
ment in cardiac tissue perfusion due to mesenchymal stem
cells,” American Journal of Physiology, Heart and Circulatory
Physiology, vol. 294, no. 5, pp. H2002–H2011, 2008.
[100] L. C. Amado, K. H. Schuleri, A. P. Saliaris et al., “Multi-
modality noninvasive imaging demonstrates in vivo cardiac
regeneration after mesenchymal stem cell therapy,” Journal of
the American College of Cardiology, vol. 48, no. 10, pp. 2116–
2124, 2006.
[101] M. Rigol, N. Solanes, J. Farr´ e et al., “Eﬀects of adipose tissue-
derived stem cell therapy after myocardial infarction: impact
of the route of administration,” Journal of Cardiac Failure,
vol. 16, no. 4, pp. 357–366, 2010.
[102] Y. Zhou, S. Wang, Z. Yu et al., “Direct injection of autologous
mesenchymal stromal cells improves myocardial function,”
Biochemical and Biophysical Research Communications, vol.
390, no. 3, pp. 902–907, 2009.
[103] J. Ma, J. Ge, S. Zhang et al., “Time course of myocardial
stromal cell-derived factor 1 expression and beneﬁcial eﬀects10 Stem Cells International
of intravenously administered bone marrow stem cells in rats
with experimental myocardial infarction,” Basic Research in
Cardiology, vol. 100, no. 3, pp. 217–223, 2005.
[104] Z. Cheng, L. Ou, X. Zhou et al., “Targeted migration
of mesenchymal stem cells modiﬁed with CXCR4 gene
to infarcted myocardium improves cardiac performance,”
Molecular Therapy, vol. 16, no. 3, pp. 571–579, 2008.
[105] Z. Cheng, X. Liu, L. Ou et al., “Mobilization of mesenchymal
stem cells by granulocyte colony-stimulating factor in rats
with acute myocardial infarction,” Cardiovascular Drugs and
Therapy, vol. 22, no. 5, pp. 363–371, 2008.
[106] J. Huang, Z. Zhang, J. Guo et al., “Genetic modiﬁcation of
mesenchymal stem cells overexpressing ccr1 increases cell
viability, migration, engraftment, and capillary density in the
injured myocardium,” Circulation Research, vol. 106, no. 11,
pp. 1753–1762, 2010.
[107] X. H. Liu, C. G. Bai, Z. Y. Xu et al., “Therapeutic potential
of angiogenin modiﬁed mesenchymal stem cells: angiogenin
improves mesenchymal stem cells survival under hypoxia
and enhances vasculogenesis in myocardial infarction,”
Microvascular Research, vol. 76, no. 1, pp. 23–30, 2008.
[108] B. Zeng, H. Chen, C. Zhu, X. Ren, G. Lin, and F. Cao, “Eﬀects
of combined mesenchymal stem cells and heme oxygenase-
1 therapy on cardiac performance,” European Journal of
Cardio-Thoracic Surgery, vol. 34, no. 4, pp. 850–856, 2008.
[109] M. Gnecchi, H. He, L. G. Melo et al., “Early beneﬁcial
effects of bone marrow-derived mesenchymal stem cells
overexpressing akt on cardiac metabolism after myocardial
infarction,” Stem Cells, vol. 27, no. 4, pp. 971–979, 2009.
[110] M. Gnecchi, H. He, N. Noiseux et al., “Evidence supporting
paracrine hypothesis for Akt-modiﬁed mesenchymal stem
cell-mediated cardiac protection and functional improve-
ment,” FASEB Journal, vol. 20, no. 6, pp. 661–669, 2006.
[111] M. Gnecchi, H. He, O. D. Liang et al., “Paracrine action
accounts for marked protection of ischemic heart by Akt-
modiﬁed mesenchymal stem cells,” Nature Medicine, vol. 11,
no. 4, pp. 367–368, 2005.
[112] H.Song,M.J.Cha,B.W.Songetal.,“Reactiveoxygenspecies
inhibit adhesion of mesenchymal stem cells implanted into
ischemic myocardium via interference of focal adhesion
complex,” Stem Cells, vol. 28, no. 3, pp. 555–563, 2010.
[113] J. Jin, S. I. Jeong, Y. M. Shin et al., “Transplantation of
mesenchymalstemcellswithinapoly(lactide-co-ε-caprolac-
tone) scaﬀold improves cardiac function in a rat myocardial
infarction model,” European Journal of Heart Failure, vol. 11,
no. 2, pp. 147–153, 2009.
[114] M. Y. Tan, W. Zhi, R. Q. Wei et al., “Repair of infarcted
myocardium using mesenchymal stem cell seeded small
intestinalsubmucosainrabbits,”Biomaterials,vol.30,no.19,
pp. 3234–3240, 2009.
[115] C. H. Chen, H. J. Wei, W. W. Lin et al., “Porous tissue
grafts sandwiched with multilayered mesenchymal stromal
cell sheets induce tissue regeneration for cardiac repair,”
Cardiovascular Research, vol. 80, no. 1, pp. 88–95, 2008.
[116] Y. Miyahara, N. Nagaya, M. Kataoka et al., “Monolayered
mesenchymal stem cells repair scarred myocardium after
myocardial infarction,” Nature Medicine, vol. 12, no. 4, pp.
459–465, 2006.
[117] A. Bel, V. Planat-Bernard, A. Saito et al., “Composite cell
sheets: a further step toward safe and eﬀective myocardial
regeneration by cardiac progenitors derived from embryonic
stemcells,”Circulation,vol.122,no.11,pp.S118–S123,2010.
[118] S.Chen,Z.Liu,N.Tianetal.,“Intracoronarytransplantation
of autologous bone marrow mesenchymal stem cells for
ischemic cardiomyopathy due to isolated chronic occluded
left anterior descending artery,” Journal of Invasive Cardiol-
ogy, vol. 18, no. 11, pp. 552–556, 2006.
[119] D. G. Katritsis, P. A. Sotiropoulou, E. Karvouni et al.,
“Transcoronary transplantation of autologous mesenchymal
stem cells and endothelial progenitors into infarcted human
myocardium,” Catheterization and Cardiovascular Interven-
tions, vol. 65, no. 3, pp. 321–329, 2005.
[120] S. L. Chen, W. W. Fang, F. Ye et al., “Eﬀect on left ventricular
function of intracoronary transplantation of autologous
bone marrow mesenchymal stem cell in patients with acute
myocardial infarction,” American Journal of Cardiology, vol.
94, no. 1, pp. 92–95, 2004.
[121] J.M.Hare,“Translationaldevelopmentofmesenchymalstem
cell therapy for cardiovascular diseases,” Texas Heart Institute
Journal, vol. 36, no. 2, pp. 145–147, 2009.
[122] J. M. Hare, J. H. Traverse, T. D. Henry et al., “A ran-
domized, double-blind, placebo-controlled, dose-escalation
study of intravenous adult human mesenchymal stem cells
(prochymal) after acute myocardial infarction,” Journal of the
American College of Cardiology, vol. 54, no. 24, pp. 2277–
2286, 2009.
[123] N. Dib, T. Henry, A. DeMaria, S. Itescu, M. M. McCarthy,
and S. C. Jaggar, “The ﬁrst US study to assess the feasibility
and safety of endocardial delivery of allogenic mesenchymal
precursor cells in patient with heart failure: three-month
interim analysis,” Circulation, vol. 120, p. S810, 2009.
[124] H. J. Duckers, J. Houtgraaf, R. J. van Geuns, B. D. van Dalen,
E. Regar, and W. van der Giessen, “First-in-man experience
with intracoronary infusion of adipose-derived regenerative
cells in the treatment of patients with ST-elevation myocar-
dial infarction: the apollo trial,” Circulation, vol. 120, Article
ID A12225, 2010.
[125] A. Schaefer, C. Zwadlo, M. Fuchs et al., “Long-term eﬀects
of intracoronary bone marrow cell transfer on diastolic
function in patients after acute myocardial infarction: 5-year
results from the randomized-controlled BOOST trial—an
echocardiographic study,” European Journal of Echocardiog-
raphy, vol. 11, no. 2, pp. 165–171, 2010.
[126] J. A. Miettinen, K. Ylitalo, P. Hedberg et al., “Determinants
of functional recovery after myocardial infarction of patients
treated with bone marrow-derived stem cells after throm-
bolytic therapy,” Heart, vol. 96, no. 5, pp. 362–367, 2009.
[127] C. Stamm, H. D. Kleine, Y. H. Choi et al., “Intramyocardial
delivery of CD133+ bone marrow cells and coronary artery
bypass grafting for chronic ischemic heart disease: safety
and eﬃcacy studies,” Journal of Thoracic and Cardiovascular
Surgery, vol. 133, no. 3, pp. 717–725, 2007.
[128] E. Martin-Rendon, S. J. Brunskill, C. J. Hyde, S. J. Stanworth,
A. Mathur, and S. M. Watt, “Autologous bone marrow
stem cells to treat acute myocardial infarction: a systematic
review,” European Heart Journal, vol. 29, no. 15, pp. 1807–
1818, 2008.
[129] T. S. Li, M. Kubo, K. Ueda, M. Murakami, A. Mikamo, and
K. Hamano, “Impaired angiogenic potency of bone marrow
cells from patients with advanced age, anemia, and renal
failure,” Journal of Thoracic and Cardiovascular Surgery, vol.
139, no. 2, pp. 459–465, 2010.
[130] C. K. Kissel, R. Lehmann, B. Assmus et al., “Selective
functional exhaustion of hematopoietic progenitor cells in
the bone marrow of patients with postinfarction heart
failure,” Journal of the American College of Cardiology, vol. 49,
no. 24, pp. 2341–2349, 2007.Stem Cells International 11
[131] S. A. Sorrentino, F. H. Bahlmann, C. Besler et al., “Oxi-
dant stress impairs in vivo reendothelialization capacity
of endothelial progenitor cells from patients with type 2
diabetes mellitus: restoration by the peroxisome proliferator-
activated receptor-γ agonist rosiglitazone,” Circulation, vol.
116, no. 2, pp. 163–173, 2007.
[132] A. J. Nauta and W. E. Fibbe, “Immunomodulatory properties
of mesenchymal stromal cells,” Blood, vol. 110, no. 10, pp.
3499–3506, 2007.
[133] J. C. Chachques, J. C. Trainini, N. Lago et al., “Myocardial
assistance by grafting a new bioartiﬁcial upgraded myocar-
dium (MAGNUM clinical trial): one year follow-up,” Cell
Transplantation, vol. 16, no. 9, pp. 927–934, 2007.